Riferimento:
Leuk Res. 2012 Nov;36(11):1398-402.
Autori:
Ikezoe T, Takeuchi A, Isaka M, Arakawa Y, Iwabu N, Kin T, Anabuki K, Sakai M, Taniguchi A, Togitani K, Yokoyama A. ikezoet@kochi-u.ac.jp
Fonte:
Leuk Res. 2012 Nov;36(11):1398-402.
Anno:
2012
Azione:
La somministrazione di trombomodulina solubile umana (rTM) in combinazione con acido all-trans retinoico (ATRA) e chemioterapia dovrebbe essere considerata utile il trattamento di pazienti con coagulazione intravascolare disseminata (DIC), causata da leucemia promielocitica acuta (APL).
Target:
rTM-ATRA-Chemioterapia/leucemia promielocitica acuta.
ABSTRACT
We treated individuals for disseminated intravascular coagulation (DIC) caused by acute promyelocytic leukemia (APL) (n=9) using human soluble thrombomodulin (rTM) in combination with all-trans retinoic acid (ATRA) and chemotherapy, and compared the clinical outcomes with historical control patients (n=8) treated with ATRA and/or chemotherapy. Two control patients developed intracranial vascular incidents. On the other hand, no bleeding related mortality was noted in rTM-treated patients. Notably, treatment with rTM rescued patients from DIC earlier than historical controls (log rank test, p=0.019). These results suggest that administration of rTM should be considered for the treatment of individuals with DIC associated with APL.
Sostanze: